ArticleFood science & nutrition2026
Cod Skin Collagen Peptides Alleviate Ulcerative Colitis by Regulating Gut Microbiota to Inhibit NLRP3 Inflammasome Activation.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enteral nutrition is an important intervention for ulcerative colitis, and collagen can improve immune responses and repair the intestinal barrier. Low-molecular-weight peptides from cod skin have demonstrated anti-inflammatory and mucosal protective effects; however, the mechanism by which they alleviate colitis through gut microbiota modulation remains unclear. This study examined the mechanism by which cod skin collagen oligopeptide powder (CP) affects the gut flora to treat ulcerative colitis (UC). This study evaluated CP in mice with dextran sodium sulfate (DSS)-induced UC and used 16S rRNA sequencing to analyze its effect on the gut flora. Fecal microbiota transplantation (FMT) demonstrated the role of CP in modulating gut microbiota in the treatment of UC. Hematoxylin and eosin staining, immunohistochemistry, histology, and enzyme-linked immunosorbent assay (ELISA) assessed CP's effects on colon structure and inflammation. 16S rRNA sequencing showed that CP therapy significantly altered the diversity and organization of the intestinal microbiota in UC mice. FMT demonstrated that CP alleviates UC by modifying the gut microbiota, providing insights into the underlying mechanisms. CP treatment significantly improved body weight, colon length, and histopathological scores in DSS-induced colitis mice, reduced the levels of NLRP3, Caspase-1, ASC, IL-1β, and IL-18, promoted colonic healing, and alleviated tissue damage. CP inhibited fibrosis by upregulating ZO-1 and Occludin while downregulating α-SMA, Vimentin, Snail, and Slug. In conclusion, CP may treat colitis in mice by suppressing NLRP3 inflammasome activation via regulation of the gut microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.